Line 5: | Line 5: | ||
<main> | <main> | ||
+ | |||
Line 35: | Line 36: | ||
</div> | </div> | ||
</section> | </section> | ||
+ | |||
+ | |||
+ | <section class="slice slice-xl bg-cover bg-size--cover" style="background-image: url('https://static.igem.org/mediawiki/2018/4/4f/T--EPFL--TeamPage.jpeg'); background-position: center bottom;"> | ||
+ | <div class="container"> | ||
+ | <div class="row justify-content-center"> | ||
+ | <div class="col-lg-9"> | ||
+ | <div class="text-center"> | ||
+ | <h2 class="heading h1 text-white"> </br> </br> </br> Won <span>Gold Medal</span></br> Nominated for: <span>Best Therapeutic Project</span> and <span>Best Software</br></ul></ui></h2> | ||
+ | <div class="btn-container mt-5"> | ||
+ | <a href="https://2018.igem.org/Team:EPFL/Awards" class="btn btn-white btn-primary btn-circle px-5">Our Awards!</a> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </section> | ||
+ | |||
<section class="slice slice-xl bg-primary" id="CAP"> | <section class="slice slice-xl bg-primary" id="CAP"> |
Revision as of 21:31, 7 December 2018
CAPOEIRA
CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay
Learn more about our projectWon Gold Medal Nominated for: Best Therapeutic Project and Best Software
What is CAPOEIRA ?
While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
This is CAPOEIRA
Bioinformatics
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells
Vaccine
Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes
Dendritic cell Activation
This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells
Follow-up
Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA